FLSW - ETF AI Analysis
Top Page
Franklin FTSE Switzerland ETF (FLSW)
FLSW, the Franklin FTSE Switzerland ETF, is supported by high-quality Swiss blue chips like Novartis, Nestlé, and Roche, whose strong financial performance, solid cash flows, and well-positioned businesses in healthcare and consumer staples underpin the fund’s overall quality. Additional strength comes from holdings such as ABB and Richemont, which add diversified industrial and luxury exposure, though some names like Lonza, Holcim, and UBS face valuation, leverage, or growth challenges that slightly weigh on the rating. The main risk factor is the ETF’s concentration in Swiss large caps and a few sectors (notably healthcare and financials), which can increase sensitivity to country- and sector-specific downturns.
FLSW vs. SPDR S&P 500 ETF (SPY)
- AUM
- 93.47M
- Region
- Europe
- Expense Ratio
- 0.09%
- Beta
- 0.61
- Issuer
- Franklin
- Inception Date
- Feb 06, 2018
- Dividend Yield
- 2.22%
- Asset Class
- Equity
- Index Tracked
- FTSE Switzerland RIC Capped Index
FLSW Summary
Franklin FTSE Switzerland ETF (FLSW) is a fund that lets you invest in a broad mix of Swiss stocks by tracking the FTSE Switzerland RIC Capped Index. It holds well-known companies like Nestlé, Roche, and Novartis, covering health care, finance, and consumer goods, along with other sectors. Someone might invest in FLSW to diversify their portfolio internationally and gain exposure to Switzerland’s stable, high-quality companies in one simple investment. A key risk is that the value of the ETF can rise or fall with the Swiss stock market and global economic conditions.
How much will it cost me?
This ETF has an expense ratio of 0.09%, which means you’ll pay about $0.90 per year for every $1,000 invested. That’s lower than the average ETF because it’s passively managed and simply tracks a Swiss stock market index instead of paying managers to pick individual stocks.
What would affect this ETF?
This Switzerland-focused ETF could benefit if the Swiss economy remains stable, global demand for healthcare and consumer staples stays strong, and major holdings like Roche, Novartis, and Nestlé continue to innovate and grow. On the negative side, it could be hurt by slower European growth, pressure on banks and insurers from interest rate or regulatory changes, currency swings in the Swiss franc, or company-specific setbacks in its large health care and financial positions.
FLSW Top 10 Holdings
This Switzerland-focused ETF leans heavily on healthcare, with Roche and Novartis acting as the main engines of performance thanks to their rising share prices and steady fundamentals. Nestlé adds a defensive consumer tilt, though its recent moves have been more mixed, slightly cooling the fund’s momentum. Financial names like UBS and Zurich Insurance are treading water, with choppy trading limiting their contribution, while luxury player Richemont has been lagging and quietly weighing on returns. Overall, it’s a concentrated bet on Swiss blue chips, all anchored firmly in the Swiss market.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NOVN | Novartis AG | 13.63% | $12.69M | CHF 244.89B | 32.49% | 80Outperform |
 CH:NESN | Nestlé SA | 12.11% | $11.27M | CHF 217.87B | 10.09% | 71Outperform |
 UBS | UBS Group AG | ― | ― | ― | ― | 73Outperform |
 SE:ABB | ABB Ltd | ― | ― | ― | ― | 78Outperform |
 CH:ZURN | Zurich Insurance Group | 3.66% | $3.40M | CHF 92.06B | 11.56% | 78Outperform |
 CH:CFR | Compagnie Financiere Richemont SA | 3.42% | $3.18M | CHF 97.29B | 5.20% | 78Outperform |
 CH:LONN | Lonza Group Ltd | 2.96% | $2.76M | CHF 43.90B | 16.96% | 71Outperform |
 CH:SREN | Swiss Re AG | 2.81% | $2.61M | CHF 41.66B | 4.81% | 73Outperform |
 CH:GALD | Galderma Group AG | 2.35% | $2.19M | CHF 44.97B | 28.96% | 70Outperform |
FLSW Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FLSW, the sentiment is Positive. The current price of 44.67 is above the 20-day moving average (MA) of 42.74, above the 50-day MA of 42.52, and above the 200-day MA of 42.27, indicating a bullish trend. The MACD of 0.63 indicates Negative momentum. The RSI at 73.98 is Negative, neither overbought nor oversold. The STOCH value of 89.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FLSW.
FLSW Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FLSW | $44.67 | $47.00(5.22% Upside) | $93.47M | 0.09% | 70Neutral |
 EWL | $65.02 | $67.56(3.91% Upside) | $3.02B | 0.50% | 71Outperform |
 FLEE | $38.38 | $45.01(17.27% Upside) | $99.39M | 0.09% | 64Neutral |
 FGM | $58.28 | $70.60(21.15% Upside) | $86.44M | 0.80% | 66Neutral |
 FLEU | $34.02 | $41.45(21.81% Upside) | $67.72M | 0.09% | 62Neutral |
 FSZ | $83.13 | $88.72(6.72% Upside) | $36.86M | 0.80% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FLSW | Franklin FTSE Switzerland ETF | 44.67 | 7.42 | 19.93% | |
| EWL | iShares MSCI Switzerland ETF | 65.02 | 10.92 | 20.18% | |
| FLEE | Franklin FTSE Europe ETF | 38.38 | 4.81 | 14.32% | |
| FGM | First Trust Germany AlphaDEX Fund | 58.28 | 1.56 | 2.76% | |
| FLEU | Franklin FTSE Eurozone ETF | 34.02 | 2.98 | 9.62% | |
| FSZ | First Trust Switzerland AlphaDEX Fund | 83.13 | 9.34 | 12.65% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.